XXXX -induced thyroid gland dysfunction.

@entity1 @entity1375 @entity2643 @entity1496 @entity3935 @entity2743
Of a population of 400 @entity1 treated with @entity2643 , 97 underwent thyroid function evaluation. Of these, 20 @entity1 proved to be @entity3935 and 16 @entity1375 . In @entity3935 @entity1 , symptoms developed 2 to 36 months after starting treatment with @entity2643 , the most specific laboratory finding being a high total T3 (TT3). No antithyroid treatment proved useful. Thyroid function returned to normal 3 to 7 months after stopping @entity2643 therapy. In the @entity1375 group, a high thyroid-stimulating hormone was the most specific laboratory finding. These @entity1 were treated with substitute therapy with or without withdrawal of @entity2643 . The @entity1496 content of the thyroid gland in part of this population taking @entity2643 was measured by in vivo x-ray fluorescence. @entity1 in whom @entity2743 developed showed especially high @entity1496 contents. During treatment with @entity2643 , @entity1 at high risk of @entity2743 were recognized by increasing TT3 values and higher @entity1496 thyroid levels. A reduction in maintenance dose should be considered in this specific population.
